GILD - Gilead Sciences, Inc.
79.82 -0.35 (-0.44%)
Pre-Market: 5:17AM EDT
| Previous Close | 81.21 |
| Open | 81.25 |
| Bid | 79.81 x 600 |
| Ask | 80.67 x 100 |
| Day's Range | 80.09 - 81.32 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 6,803,362 |
| Avg. Volume | 9,412,544 |
| Market Cap | 104.7B |
| Beta | 0.90 |
| PE Ratio (TTM) | 8.71 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.56%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
Yahoo Finance Video•5 days agoGilead shares up after FDA approves breakthrough cancer treatment
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
Yahoo Finance Video•5 days agoNike hit with downgrade, Blue Apron cutting jobs, Gilead new cancer drug gets FDA approval
Verizon, American Express, Nike, Blue Apron and Gilead Sciences are among the stocks to watch.
- Investor's Business Daily•6 hours ago
IBD's No. 1 Group Is Under Pressure; These 6 Key Earnings Loom; S&P 500 Futures
Biotechs have been big winners in 2017, but the group and several top stocks have been drifting lower, testing key levels. Biogen reports earnings Tuesday, with Amgen, Vertex, Gilead, Celgene and Alexion later this week.
- Market Realist•14 hours ago
What Analysts Project for Eli Lilly in 3Q17
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
- Investopedia•16 hours ago
How Earnings Will Fuel Biotech's Bull Run: BMO Capital
Biogen, Gilead could have beat-and-raise quarters, with Vertex and Incyte also doing well
- Motley Fool•18 hours ago
Why Agenus Inc. Stock Briefly Popped Today
After the market had time to reflect on Agenus' new CAR-T venture, investors were unimpressed by its prospects.
- Capital Cube•19 hours ago
Gilead Sciences, Inc. – Value Analysis (NASDAQ:GILD) : October 23, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Gilead Sciences, Inc. a score of 66. Our analysis is based on comparing Gilead Sciences, Inc. with the following peers – Amgen Inc., Vertex Pharmaceuticals Incorporated, Celgene Corporation, Alexion Pharmaceuticals, Inc., AbbVie, Inc., Illumina, Inc., Biogen Inc., Eli Lilly and Company, Merck & Co., Inc. and Johnson ... Read more (Read more...)
- Zacks•20 hours ago
Is Gilead (GILD) Poised for a Beat This Earnings Season?
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
- Motley Fool•22 hours ago
3 Gene Therapy Stocks That Could Make You Rich
Even risk-averse investors can find exposure to one of the hottest trends in healthcare.
- Motley Fool•23 hours ago
3 Things You Should Expect in Gilead Sciences' Q3 Results
Hepatitis C probably won't be the biggest story for the biotech.
- The Wall Street Journal•3 days ago
[$$] The Business of Saving Lives
Gilead Science’s executive chairman talks about the new era of biomedicine and why drugs cost so much, as Donald Trump has noticed.
- Zacks•3 days ago
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval
Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.
- Zacks•4 days ago
Cancer Treatment Update: Second Gene Therapy Receives Approval
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
- Market Realist•4 days ago
Gilead Sciences Stock: Performance in 3Q17
Gilead Sciences stock has risen ~15.2% in 3Q17 and 13.9% year-to-date as of October 20, 2017.
- Capital Cube•4 days ago
Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : October 20, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Gilead Sciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- Motley Fool•4 days ago
Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Celgene's partnership strategy gives it exposure to multiple companies' research on next-generation cell therapy.
- The Wall Street Journal•4 days ago
[$$] Gormley's Take: Gene Therapy Finally Hitting Pay Dirt
After decades of dreams unfulfilled, gene therapy is finally having its day in the sun.
- Motley Fool•4 days ago
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Sciences' premium price for Yescarta could help offset hep C headwinds.
- TheStreet.com•5 days ago
FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma
Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
- Investor's Business Daily•5 days ago
Does Gilead Now Have A New Multi-Billion-Dollar Franchise?
Gilead jumped early Thursday after the FDA approved its CAR-T drug, dubbed Yescarta, to treat Non-Hodgkin lymphoma.
- Benzinga•5 days ago
Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug
The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD )'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost ...
- InvestorPlace•5 days ago
3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
- Yahoo Finance•5 days ago
Nike hit with downgrade, Blue Apron cutting jobs, Gilead new cancer drug gets FDA approval
Verizon, American Express, Nike, Blue Apron and Gilead Sciences are among the stocks to watch.
- TheStreet.com•5 days ago
Gilead Sciences Yescarta Drug Approved By FDA
Shares of Gilead Sciences rose 2% Thursday after the FDA approved its Yescarta lymphoma cancer therapy drug.
- Barrons.com•5 days ago
Gilead: Congratulations…But You Still Overpaid for Kite
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
